 SEATTLE, May 04, 2021 GLOBE NEWSWIRE -- Chinook Therapeutics, Inc. Nasdaq: KDNY, a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Companys Board of Directors approved new employment inducement grants of stock options to purchase a total of 125,267 shares of common stock with a grant date of April 30, 2021 the Inducement Grants for two new employees. 